TNN - jaargang 126, nummer 5, september 2025
drs. R.H.J. Janssens , drs. J.P.M. van de Mortel , dr. K.S. Jie , dr. S. Lassche , prof. dr. N.C. Notermans
Anti-MAG-polyneuropathie is een subgroep van de M-proteïne-gerelateerde polyneuropathieën, veroorzaakt door pathogene antilichamen tegen MAG (‘myelin associated glycoprotein’) en kan sterk invaliderende klachten geven. Rituximab is op dit moment de enige bewezen behandeling, maar de effectiviteit is beperkt. Daarom zijn nieuwe behandelopties noodzakelijk.
(TIJDSCHR NEUROL NEUROCHIR 2025;126(5):196–200)
Lees verder
Naar boven
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
